Written by Asif Dewan, Managing Director of Medical Cannabis Clinic Alternaleaf
On Tuesday, Work and Pensions Minister Liz Kendall unveiled Labour’s ambitious plan to address economic inactivity, aiming to get 2.8 million people back into work.
The focus is on improving British health is central to this effort. The UK unemployment rate lags behind many of our European neighbours and most OECD nations. Long-term illness in the UK is a major cause.
Embracing medical cannabis as a legitimate treatment option could be pivotal in this mission. Since its legalisation in 2018, medical cannabis has been proven to safely treat over fifty conditions, including chronic pain, anxiety, and depression.
Despite its potential for getting people back to work, NHS prescriptions for medical cannabis remain exceedingly rare – the last records suggested only five patients were being prescribed it via the NHS and for limited conditions.
This has not stopped British people from legally accessing treatment, they’ve just gone private. Prescriptions for Cannabis-Based Products for Medicinal Use (CBPM) more than doubled between 2022 and 2023 when 177,566 items were dispensed. As awareness increases, this is set to rise.
Almost eight in ten (76%) of our patients are employed in sectors like nursing, teaching, hospitality and technology. And many who were previously unemployed due to long-term illness are now back to work because of medical cannabis. Patients like Sarah, who suffers from Hyper Mobility Syndrome, and Steve, who struggled with the physical and mental impact of a road traffic accident, have experienced life-changing improvements through medical cannabis, allowing them to return to work.
If the Work and Pensions Minister needs more reassurance on the link between medical cannabis and improved societal health, countries like Germany and Canada offer promising examples. Germany’s embrace of medical cannabis since 2017 has improved patients’ quality of life, while Canada’s legalisation has reduced opioid prescriptions and related deaths.
By improving access to medical cannabis, we can alleviate NHS waiting lists, currently at an unprecedented 7.57 million cases, and support the government’s efforts to enhance the health and productivity of our nation. A healthy society is a productive one, and medical cannabis could be a crucial component in combating economic inactivity.
Embracing Medical Cannabis Treatment Will Get People Back to Work
Written by Asif Dewan, Managing Director of Medical Cannabis Clinic Alternaleaf
On Tuesday, Work and Pensions Minister Liz Kendall unveiled Labour’s ambitious plan to address economic inactivity, aiming to get 2.8 million people back into work.
The focus is on improving British health is central to this effort. The UK unemployment rate lags behind many of our European neighbours and most OECD nations. Long-term illness in the UK is a major cause.
Embracing medical cannabis as a legitimate treatment option could be pivotal in this mission. Since its legalisation in 2018, medical cannabis has been proven to safely treat over fifty conditions, including chronic pain, anxiety, and depression.
Despite its potential for getting people back to work, NHS prescriptions for medical cannabis remain exceedingly rare – the last records suggested only five patients were being prescribed it via the NHS and for limited conditions.
This has not stopped British people from legally accessing treatment, they’ve just gone private. Prescriptions for Cannabis-Based Products for Medicinal Use (CBPM) more than doubled between 2022 and 2023 when 177,566 items were dispensed. As awareness increases, this is set to rise.
Almost eight in ten (76%) of our patients are employed in sectors like nursing, teaching, hospitality and technology. And many who were previously unemployed due to long-term illness are now back to work because of medical cannabis. Patients like Sarah, who suffers from Hyper Mobility Syndrome, and Steve, who struggled with the physical and mental impact of a road traffic accident, have experienced life-changing improvements through medical cannabis, allowing them to return to work.
If the Work and Pensions Minister needs more reassurance on the link between medical cannabis and improved societal health, countries like Germany and Canada offer promising examples. Germany’s embrace of medical cannabis since 2017 has improved patients’ quality of life, while Canada’s legalisation has reduced opioid prescriptions and related deaths.
By improving access to medical cannabis, we can alleviate NHS waiting lists, currently at an unprecedented 7.57 million cases, and support the government’s efforts to enhance the health and productivity of our nation. A healthy society is a productive one, and medical cannabis could be a crucial component in combating economic inactivity.
Global Medical Cannabis Market Review 2026
A comprehensive analysis of the international medical cannabis supply chain — examining country-specific data on exports, imports, market size, domestic production, and distribution landscapes. Understand the driving forces behind global supply dynamics, the impact of telemedicine on patient access, and regulatory changes shaping the market.
What's covered
Premium Data Packs
Save 15%Pre-register for the Free Report
Be the first to receive the Global Medical Cannabis Market Review 2026 when it publishes in January.
Script Assist Expands Reach with Three New Medical Cannabis Partners
Next PostNew Report on Germany’s Medical Cannabis Market Indicates That It Is Prepared For Rapid Growth
Business of Cannabis
Business of Cannabis is the source for news, analysis, and insights on the global cannabis industry, providing business leaders, investors, policymakers, and entrepreneurs with data-driven coverage of markets, regulation, and innovation shaping the sector.
Related Posts
Related Posts
The Battle for Germany’s Medical Cannabis Market: Who’s Fighting for What
Today, (Wednesday, January 14), a public hearing will bring together 22 hand-picked experts for a debate on the future country's...
UK Police Finally Get Official Medical Cannabis Guidance More Than 7 Years After Legalisation
Over seven years after medical cannabis was legalised in the UK, the National Police Chiefs' Council has approved the first...
Germany’s Medical Cannabis Bill Faces Critical Test as Experts Warn of ‘Unenforceable’ Framework
Industry Leaders React to Historic Cannabis Rescheduling
CBD Company Founder Wins £137k Unfair Dismissal Award Amid Cannim Group Collapse
Veterans and Medical Cannabis: Can Private Clinics Fill NHS Treatment Gaps?
Cannabis Europa Paris
Europe’s leading cannabis policy, business and investment conference — bringing senior decision-makers together in Paris.
CONNECT
Related Posts
Related Posts
UK Police Finally Get Official Medical Cannabis Guidance More Than 7 Years After Legalisation
Over seven years after medical cannabis was legalised in the UK, the National Police Chiefs' Council has approved the first...
Germany’s Medical Cannabis Bill Faces Critical Test as Experts Warn of ‘Unenforceable’ Framework
As Trump's rescheduling executive order dominated the cannabis industry’s attention over the holiday period, Germany's controversial medical cannabis bill quietly...
Industry Leaders React to Historic Cannabis Rescheduling
President Donald Trump's executive order directing federal agencies to move cannabis from Schedule I to Schedule III of the Controlled...
CBD Company Founder Wins £137k Unfair Dismissal Award Amid Cannim Group Collapse
Last month, international cannabis operator Cannim collapsed, calling in administrators to sift through the company's remaining assets and attempt to...
Veterans and Medical Cannabis: Can Private Clinics Fill NHS Treatment Gaps?
The UK’s health service is fighting to keep its head above water, yet with a record-breaking winter flu pandemic sweeping...
Recent Posts
Related Posts
Veterans and Medical Cannabis: Can Private Clinics Fill NHS Treatment Gaps?
The UK’s health service is fighting to keep its head above water, yet with a record-breaking winter flu pandemic sweeping...
‘Blockbuster’ Cannabis Drug To Be Released in 2026
Findings from the successful trials of a new, multi-compound, cannabis medicine look set to deliver a major breakthrough for the...
There’s No UK Cannabis Industry Without UK Cultivation
The UK economic growth faces a paradox of two seemingly opposing pressures, yet both may be resolved by moving in...
How to Read a Cannabis Research Paper
Why Reading Research Matters The volume of cannabis research has never been higher, but not all studies are created equal....
SOMAÍ Adds International Lifestyle Brand Cookies to Global Medical Cannabis Markets
Cookies, the most globally recognised cannabis brand, is entering global medical markets with a full extract portfolio through a strategic...
Subscribe to our mailing list to receives daily updates!
We won’t spam you
Categories
Browse by Tags